An investigational drug known as APT102 significantly reduced damage to heart muscle from a heart attack and minimized the risk of bleeding during follow-up treatments, according to an animal study based on a decade of work by APT Therapeutics, scientists at Washington University School of Medicine in St. Louis and colleagues at Cornell and Harvard.
Standard heart attack treatment often causes heart tissue damage. Once the blood clot that causes a heart attack is removed from an artery, molecules from dead and dying cells mix with blood rushing back through the artery. One of these molecules, adenosine triphosphate (ATP), is inflammatory; another, adenosine diphosphate (ADP), causes more clotting.
“ATP and ADP have different roles, but they both lead to more heart damage as they flood through the reopened artery after a heart attack,” said senior author Dana Abendschein, PhD, associate professor of medicine and of cell biology and physiology at Washington University.
APT102, invented and patented by APT Therapeutics, is a genetically-engineered version of the human protein apyrase, which transforms ATP and ADP into a benign molecule, adenosine monophosphate. Another enzyme changes this molecule into adenosine, which is beneficial for the heart.
“Adenosine opens the blood vessels, increases blood flow and also has a protective effect on the lining of the vessels,” said Abendschein. “It takes the bad products away and produces a good byproduct that’s protective.”
The scientists treated 21 dogs for the study. After the clots that caused their heart attacks were dissolved using medication, eight received the standard post heart-attack drug clopidogrel, a blood thinner; seven were given low doses of APT102; and six were given high doses of APT102.
The researchers found that treatment with APT102 significantly reduced the amount of irreversible heart muscle damage.
“That’s a huge benefit because the majority of patients who have a lot of heart muscle damage go on to have heart failure,” Abendschein said.
By breaking down the clotting factor ADP, treatment with APT102 also eliminated the return of the clots, which can lead to further heart damage.
“Virtually every agent that’s being used in patients now to prevent clot formation blocks the blood clotting agents known as platelets, and that creates a risk of bleeding,” Abendschein said. “This is not true of APT102.”
Other anticlotting agents have to be digested and converted into their active form in the liver, but APT102 can be injected directly into a vein, where it works immediately.
“When it comes to heart attack treatment, the saying is ‘time is muscle’ — the longer you delay treatment, the more irreversible damage the heart will suffer,” Abendschein said. “APT102 may help us save critical time by letting treatment start right away.”
The researchers hope to start clinical trials of the drug in people within the next year.
Citation: Moeckel D, Jeong SS, Sun X, Broekman MJ, Nguyen A, Drosopoulos JHF, Marcus AJ, Robson SC, Chen R, Abendschein D. Optimizing human apyrase to treat arterial thrombosis and limit reperfusion injury without increasing bleeding risk. Science Translational Medicine, Aug. 6, 2014.
- PHYSICAL SCIENCES
- EARTH SCIENCES
- LIFE SCIENCES
- SOCIAL SCIENCES
Subscribe to the newsletter
Stay in touch with the scientific world!
Know Science And Want To Write?
- Sweet Irony: The Environmental Impacts Of GMO Sugar Science Denial
- Evidence Of Link Between Childhood Cancer And Phototherapy For Jaundice Examined
- How Does Obesity Cause Disease In Organs Distant From Those Where Fat Accumulates?
- Sexual Harassment in Science What Have We Learned (OP ED)
- Hacking Memory To Follow Through With Intentions
- Distinguished European Scientists Challenge Endocrine Pseudoscience
- Flu Vaccination Associated With Lower Dementia Risk In Patients With Heart Failure
- "No, I am not saying a lack of belief will result in research showing something does not work. There..."
- "I think the text is quite easy to comprehend considering the difficulty of the subject matter...."
- "If you find a food without chemicals, please let the world know. You will get the biggest Nobel..."
- "Hi Tommaso, I think that the explanation can be understood with a bit of effort. However I am pretty..."
- "Are you saying that because scientists don't believe in homeopathy then scientific trials won't..."
- When it comes to replicating studies, context matters, an analysis of reproducibility pro
- Squids on the rise as oceans change
- Loss of Y chromosome in blood is associated with developing Alzheimer's disease
- New disease gene will lead to better screening for pediatric heart disease
- Enhanced arginine metabolism may counteract inflammation pathways in asthma